apremilast
Evotec appoints Ingrid Müller as Chief Operating Officer
Most recently, Müller held senior international leadership roles at CureVac, Sanofi and Fresenius Kabi
smartbax licenses compound from Aicuris for next-generation antibiotic development
The new programme addresses the urgent unmet medical need for new therapies to tackle antibiotic-resistant infections
Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities
Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity
Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions
New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...
BMS and Bain Capital launch new company to develop immunology therapies
The newly formed company has in-licensed five investigational immunology drugs from BMS
AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition
The deal includes a CAR-T therapy in phase 1 development for B cell-mediated autoimmune diseases
Sanofi to expand immunology capabilities with $9.5bn Blueprint acquisition
The deal will grant Sanofi access to a drug approved for the rare immunologic disorder systemic mastocytosis
AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies
The companies will focus on developing therapeutics across neuroscience, immunology and oncology
Sanofi expands immunology pipeline by acquiring Dren’s bispecific for $600m upfront
The candidate has shown potential in treating B-cell mediated autoimmune diseases
AbbVie and Neomorph enter molecular glue degrader partnership worth $1.64bn
The companies are aiming to develop MGDs for targets across oncology and immunology
AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition
The deal includes an IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease
Novartis and Schrödinger to advance drug candidates in deal worth over $2.4bn
The companies will advance therapeutics for undisclosed targets in Novartis’ core areas